Index to volume 51

Author index

A

Aarbakke J (*see* Klemetsdal et al). 1992;51:24-31
Abernethy DR. Notes of the American Society for Clinical Pharmacology and Therapeutics: a message from the president—come to Orlando, March 18-20, 1992. 1992;51:93
——. Presidential address: Orlando, Florida, March 18, 1992. 1992;51:475-77
Adamus WS (*see* Schilling et al). 1992;51:541-8
Alessandri M (*see* Fanciullacci et al). 1992;51:302-7
Allen A (*see* Sindrup et al). 1992;51:278-87
Allen GD (*see* Sindrup et al). 1992;51:278-87
Alvarez MP (*see* Azanza et al). 1992;51:572-5
Ams PA (*see* May et al). 1992;51:689-700
Averbuch M (*see* Weintraub et al). 1992;51:608-14
—— (*see* Weintraub et al). 1992;51:615-8
Azanza JR, Catalán M, Alvarez MP, Sádaba B, Honorato J, Llorens R, Herreros J. Possible interaction between cyclosporine and josamycin: a description of three cases. 1992;51:572-5

B

Balder A (*see* Weintraub et al). 1992;51:586-94
—— (*see* Weintraub et al). 1992;51:595-601
Barlascini N (*see* Hunt et al). 1992;51:18-23
Barr WH (*see* Peck et al). 1992;51:465-73 (Conference report)
Baurain R (*see* Canal et al). 1992;51:249-59
Beasley R (*see* Woodman et al). 1992;51:566-71
Beatrice S (*see* Fanciullacci et al). 1992;51:302-7
Beaver WT (*see* Forbes et al). 1992;51:343-52
Bellissant E, Thuillez C, Pussard E, Giudicelli J-F. Systemic and regional hemodynamic effects of zabicipril in healthy volunteers. 1992;51:308-19
Belpomme D (*see* Canal et al). 1992;51:249-59
Benedetti TL (*see* Pritchard et al). 1992;51:51-5
Benet LZ (*see* Peck et al). 1992;51:465-73 (Conference report)
Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. 1992;51:239-48
Berry EM (*see* Caraco et al). 1992;51:501-6
Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. 1992;51:388-97
Biollaz J (*see* Munafo et al). 1992;51:513-21
Bishop AL (*see* Martyn et al). 1992;51:408-14
Bjornsson TD. The method of relative drug accumulation: a simple method for illustrating the effects of different drug dosing regimens and variability in drug elimination on time courses of drug concentrations. 1992;51:266-70
Blaschke TF (*see* Vincent et al). 1992;51:68-75
Blouin RA (*see* Colangelo et al). 1992;51:489-94
—— (*see* Colangelo et al). 1992;51:549-54
Bluhm R (*see* Branch et al). 1992;51:481-8 (Commentary)
Bochner F (*see* Somogyi et al). 1992;51:379-87
Borland RM (*see* Munafo et al). 1992;51:513-21
Bosco O (*see* Funck-Brentano et al). 1992;51:507-12
Branch RA, Johnston PE, Koestner JA, Bluhm R, Stratton CW, Knight JR. The formulary: an educational tool for clinical pharmacology. 1992;51:481-8 (Commentary)
—— (*see* May et al). 1992;51:689-700
Breimer DD (*see* Mandema et al). 1992;51:715-28
Bremner KE (*see* Naranjo et al). 1992;51:729-39
Briccolani-Bandini E (*see* Fanciullacci et al). 1992;51:302-7
Britto MR (*see* Zhang et al). 1992;51:647-55
Brøsen K (*see* Sindrup et al). 1992;51:278-87
—— (*see* Sindrup et al). 1992;51:288-95
Brunner F (*see* Stoschitzky et al). 1992;51:445-53
Brunner HR (*see* Munafo et al). 1992;51:513-21
Bryson JC (*see* Pritchard et al). 1992;51:51-5
Bugat R (*see* Canal et al). 1992;51:249-59
Burgess C (*see* Woodman et al). 1992;51:566-71
Burlew BS (*see* Johnson and Burlew). 1992;51:495-500
Byrne L (*see* Weintraub et al). 1992;51:595-601
—— (*see* Weintraub et al). 1992;51:608-14
—— (*see* Weintraub et al). 1992;51:615-8

C

Canal P, Robert J, Ramon M, Baurain R, Tresca P, de Forni M, Marty M, Pujade-Lauraine E, Bugat R, Magis A, Belpomme D. Human pharmacokinetics of *N*-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. 1992;51:249-59
Cannon M (*see* Gupta et al). 1992;51:56-67
Caraco Y, Zylber-Katz E, Berry EM, Levy M. Significant weight reduction in obese subjects enhances carbamazepine elimination. 1992;51:501-6
Cardillo C, Degen C, De Felice F, Folli G. Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension. 1992;51:555-61
Cass WA (*see* Zahniser et al). 1992;51:432-9
Catalán M (*see* Azanza et al). 1992;51:572-5
Chandler MHH (*see* Clifton et al). 1992;51:296-301
Chay PCW, Duffy BJ, Walker JS. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. 1992;51:334-42
Chiang ST (*see* Troy et al). 1992;51:271-7
Christen Y (*see* Munafo et al). 1992;51:513-21

January, pp. 1-120; February, pp. 121-228; March, pp. 229-358; April, pp. 359-480; May, pp. 481-646; June, pp. 647-768.

Clair WK, Wilkinson WE, McCarthy EA, Pritchett ELC. Treatment of paroxysmal supraventricular tachycardia with oral diltiazem. 1992;51:562-5
Claypool WD (*see* Page et al). 1992;51:371-8
Clifton GD, Chandler MHH, Pennell AT, McCoy RA, Harrison MR. Differential response of β-adrenergic receptor–mediated heart rate and aortic blood flow acceleration to timolol. 1992;51:296-301
Cohen AF (*see* Mandema et al). 1992;51:715-28
Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, DeMaria AN, Wedlund PJ. Age and β-adrenergic receptor sensitivity to S(−)- and R,S(±)-propranolol in humans. 1992;51:549-54
——, ——, ——, ——, ——, ——. Age and propranolol stereoselective disposition in humans. 1992;51:489-94
Collins J (*see* Peck et al). 1992;51:465-73 (Conference report)
Conrad K (*see* Troy et al). 1992;51:271-7
Cooper SM (*see* Sindrup et al). 1992;51:278-87
Cox C (*see* Weintraub et al). 1992;51:586-94
—— (*see* Weintraub et al). 1992;51:608-14
—— (*see* Weintraub et al). 1992;51:619-33
Crane J (*see* Woodman et al). 1992;51:566-71
Cravioto J (*see* Lares-Asseff et al). 1992;51:42-50
Cretton EM (*see* Stagg et al). 1992;51:668-76
Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. 1992;51:522-26
—— (*see* Gupta et al). 1992;51:56-67
Curella P (*see* Zahniser et al). 1992;51:432-9

D

Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. 1992;51:12-7
Daneman D (*see* Gupta et al). 1992;51:56-67
Danhof M (*see* Mandema et al). 1992;51:715-28
DeCastro A (*see* Sunshine et al). 1992;51:740-6
De Felice F (*see* Cardillo et al). 1992;51:555-61
de Forni M (*see* Canal et al). 1992;51:249-59
Degen C (*see* Cardillo et al). 1992;51:555-61
DeMaria AN (*see* Colangelo et al). 1992;51:489-94
—— (*see* Colangelo et al). 1992;51:549-54
Desjardins RE (*see* Peck et al). 1992;51:465-73 (Conference report)
Diasio RB (*see* Stagg et al). 1992;51:668-76
Dohrmann ML (*see* Lee and Dohrmann). 1992;51:353-5
Du YL (*see* Bertilsson et al). 1992;51:388-97
Duffy BJ (*see* Chay et al). 1992;51:334-42
Dutta A (*see* Johnson et al). 1992;51:32-41

E

Echizen H (*see* Ohnishi et al). 1992;51:454-64
Eddy AC (*see* Heimark et al). 1992;51:398-407
—— (*see* O'Reilly et al). 1992;51:656-67
Edquist IA (*see* Forbes et al). 1992;51:343-52
Egginger G (*see* Stoschitzky et al). 1992;51:445-53
Eggo MC (*see* Gupta et al). 1992;51:56-67
Elliott HL, Macdonald NJ, Meredith PA, Reid JL. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril. 1992;51:260-5
—— (*see* Meredith and Elliott). 1992;51:708-14

F

Fanciullacci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S. Long-term ergotamine abuse: effect on adrenergically induced mydriasis. 1992;51:302-7
Faulkner R (*see* Johnson et al). 1992;51:32-41
Fisher LE, Ludwig EA, Wald JA, Sloan R, Middleton E Jr, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 AM versus 4 PM. 1992;51:677-88
Fleming CM (*see* May et al). 1992;51:689-700
Foley KM (*see* Portenoy et al). 1992;51:422-31
Folli G (*see* Cardillo et al). 1992;51:555-61
Forbes JA, Beaver WT, Jones KF, Edquist IA, Gongloff CM, Smith WK, Smith FG, Schwartz MK. Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain. 1992;51:343-52
Friedlander-Klar H (*see* Portenoy et al). 1992;51:422-31
Friedman IM (*see* Page et al). 1992;51:371-8
Fujiwara H (*see* Ohnishi et al). 1992;51:454-64
Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. 1992;51:507-12
Furst DE (*see* Peck et al). 1992;51:465-73 (Conference report)

G

Gardiner P (*see* Page et al). 1992;51:371-8
Gerber JG (*see* Zahniser et al). 1992;51:432-9
Gerlag PGG (*see* van Meyel et al). 1992;51:440-4
Gibaldi M (*see* Heimark et al). 1992;51:398-407
—— (*see* O'Reilly et al). 1992;51:656-67
Ginsberg G (*see* Weintraub et al). 1992;51:595-601
Gisholt K (*see* Klemetsdal et al). 1992;51:24-31
Giudicelli JF (*see* Bellissant et al). 1992;51:308-19
Gongloff CM (*see* Forbes et al). 1992;51:343-52
Gotch FA (*see* Uehlinger et al). 1992;51:76-89
Goulart DA (*see* Heimark et al). 1992;51:398-407
—— (*see* O'Reilly et al). 1992;51:656-67
Gram LF (*see* Sindrup et al). 1992;51:278-87
—— (*see* Sindrup et al). 1992;51:288-95
Greene DS (*see* Johnson et al). 1992;51:32-41
Gribnau FWJ (*see* van Meyel et al). 1992;51:440-4
Gupta A, Eggo MC, Uetrecht JP, Cribb AE, Daneman D, Rieder MJ, Shear NH, Cannon M, Spielberg SP. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. 1992;51:56-67
Guzelian PS (*see* Hunt et al). 1992;51:18-23

H

Halabi A (*see* Kirch et al). 1992;51:325-33
Hallas J (*see* Sindrup et al). 1992;51:278-87
Halstenson CE (*see* Johnson et al). 1992;51:32-41
Hantsbarger G (*see* Rainsford et al). 1992;51:415-21
Harrison MR (*see* Clifton et al). 1992;51:296-301
Harter JG (*see* Peck et al). 1992;51:465-73 (Conference report)
Hawkins ES, Reich MR. Japanese-originated pharmaceutical products in the United States from 1960 to 1989: an assessment of innovation. 1992;51:1-11 (Commentary)
Haynes J (*see* Johnson et al). 1992;51:32-41
Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the interaction between amiodarone and warfarin in humans. 1992;51:398-407
Henry JA (*see* Hla et al). 1992;51:366-70
Herreros J (*see* Azanza et al). 1992;51:572-5
Hicks DR (*see* Troy et al). 1992;51:271-7
Himberg JJ (*see* Mustajoki et al). 1992;51:320-4
Hinrichsen H (*see* Kirch et al). 1992;51:325-33
Hla KK, Latham AN, Henry JA. Influence of time of administration on verapamil pharmacokinetics. 1992;51:366-70
Hoffman BB (*see* Vincent et al). 1992;51:68-75
Honorato J (*see* Azanza et al). 1992;51:572-5
Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, Wright JT Jr, Guzelian PS. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. 1992;51:18-23
Hunt RH (*see* Rainsford et al). 1992;51:415-21

I

Ingelman-Sundberg M (*see* Dahl et al). 1992;51:12-7
Inturrisi CE (*see* Portenoy et al). 1992;51:422-31
Iselius L (*see* Bertilsson et al). 1992;51:388-97
Ishizaki T (*see* Ohnishi et al). 1992;51:454-64

J

Jacqz-Aigrain E (*see* Funck-Brentano et al). 1992;51:507-12
Jaillon P (*see* Funck-Brentano et al). 1992;51:507-12
James C (*see* Rainsford et al). 1992;51:415-21
Johansson I (*see* Dahl et al). 1992;51:12-7
Johnsen K (*see* Klemetsdal et al). 1992;51:24-31
Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS, Kuye O. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. 1992;51:32-41
Johnson JA, Burlew BS. Racial differences in propranolol pharmacokinetics. 1992;51:495-500
Johnston PE (*see* Branch et al). 1992;51:481-8 (Commentary)
Jones KF (*see* Forbes et al). 1992;51:343-52
Jusko WJ (*see* Fisher et al). 1992;51:677-88

K

Karim A (*see* Page et al). 1992;51:371-8
—— (*see* Rainsford et al). 1992;51:415-21
Kelloway JS (*see* Johnson et al). 1992;51:32-41
Kemodle AE (*see* Pritchard et al). 1992;51:51-5
Keundjian A (*see* Funck-Brentano et al). 1992;51:507-12
Kidd L (*see* Stagg et al). 1992;51:668-76
Kirch W, Halabi A, Hinrichsen H. Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. 1992;51:325-33
Klein W (*see* Stoschitzky et al). 1992;51:445-53
Klemetsdal B, Tollefsen E, Loennechen T, Johnsen K, Utsi E, Gisholt K, Wist E, Aarbakke J. Interethnic difference in thiopurine methyltransferase activity. 1992;51:24-31
Knight JR (*see* Branch et al). 1992;51:481-8 (Commentary)
Koestner JA (*see* Branch et al). 1992;51:481-8 (Commentary)
Kolars J (*see* Lown et al). 1992;51:229-38
Kowalski KG (*see* Page et al). 1992;51:371-8
Kraml M (*see* Troy et al). 1992;51:271-7
Kroboth PD (*see* Schmith et al). 1992;51:533-40
Kuang T-Y (*see* Bertilsson et al). 1992;51:388-97
Kunze K (*see* Heimark et al). 1992;51:398-407
Kunze KL (*see* O'Reilly et al). 1992;51:656-67
Kuye O (*see* Johnson et al). 1992;51:32-41

L

Laitinen LA (*see* Strömberg et al). 1992;51:527-32
Lanctot KL (*see* Naranjo et al). 1992;51:729-39
Lares-Asseff I, Cravioto J, Santiago P, Pérez-Ortíz B. Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children. 1992;51:42-50
Lasagna L (*see* Weintraub et al). 1992;51:586-94
Latham AN (*see* Hla et al). 1992;51:366-70
Lee BL, Dohrmann ML. Theophylline toxicity after propafenone treatment: evidence for drug interaction. 1992;51:353-5
Lee RJ (*see* Munafo et al). 1992;51:513-21
Lemberger L (*see* Bergstrom et al). 1992;51:239-48
Levy G (*see* Peck et al). 1992;51:465-73 (Conference report)
Levy M (*see* Caraco et al). 1992;51:501-6
Liao XM (*see* Bertilsson et al). 1992;51:388-97
Lindner W (*see* Stoschitzky et al). 1992;51:445-53
Lindqvist A (*see* Strömberg et al). 1992;51:527-32
Liu Y (*see* Bertilsson et al). 1992;51:388-97
Llorens R (*see* Azanza et al). 1992;51:572-5
Loennechen T (*see* Klemetsdal et al). 1992;51:24-31
Lou YQ (*see* Bertilsson et al). 1992;51:388-97
Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. 1992;51:229-38
Ludden T (*see* Peck et al). 1992;51:465-73 (Conference report)
Ludwig EA (*see* Fisher et al). 1992;51:677-88

M

Macdonald NJ (*see* Elliott et al). 1992;51:260-5
Madan M (*see* Weintraub et al). 1992;51:586-94
—— (*see* Weintraub et al). 1992;51:595-601
Madden T, Sunderland M, Santana VM, Rodman JH. The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. 1992;51:701-7
Magis A (*see* Canal et al). 1992;51:249-59
Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. 1992;51:715-28
Marty M (*see* Canal et al). 1992;51:249-59
Martyn JAJ, Bishop AL, Oliveri MF. Pharmacokinetics and pharmacodynamics of ranitidine after burn injury. 1992;51:408-14
May DG, Ams PA, Richards WO, Porter J, Ryder D, Fleming CM, Wilkinson GR, Branch RA. The disposition of dapsone in cirrhosis. 1992;51:689-700
McCarthy EA (*see* Clair et al). 1992;51:562-5
McCoy RA (*see* Clifton et al). 1992;51:296-301
McDonald SJ (*see* Page et al). 1992;51:371-8
McNamara PJ (*see* Colangelo et al). 1992;51:489-94
—— (*see* Colangelo et al). 1992;51:549-54
Mellows G (*see* Sindrup et al). 1992;51:278-87
Meredith PA, Elliott HL. An additive or synergistic drug interaction: application of concentration-effect modeling. 1992;51:708-14
—— (*see* Elliott et al). 1992;51:260-5
Merion R (*see* Lown et al). 1992;51:229-38
Meyer BR. Biotechnology and therapeutics: expensive treatments and limited resources. A view from the hospital. 1992;51:359-65 (Commentary)
Middleton E Jr (*see* Fisher et al). 1992;51:677-88
Minn FL (*see* Sunshine et al). 1992;51:740-6
Moscucci M (*see* Weintraub et al). 1992;51:602-7
Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. 1992;51:513-21
Mustajoki P, Himberg JJ, Tokola O, Tenhunen R. Rapid normalization of antipyrine oxidation by heme in variegate porphyria. 1992;51:320-4

N

Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. 1992;51:729-39
Neal J (*see* O'Reilly et al). 1992;51:656-67
Nicholson PA (*see* Rainsford et al). 1992;51:415-21
Nies AS (*see* Zahniser et al). 1992;51:432-9
Nussberger J (*see* Munafo et al). 1992;51:513-21

O

Obermayer-Pietsch B (*see* Stoschitzky et al). 1992;51:445-53
Ohnishi A, Ishizaki T, Echizen H, Yasuda K, Fujiwara H, Tanaka T. Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans. 1992;51:454-64
Oliveri MF (*see* Martyn et al). 1992;51:408-14
Olkkola KT (*see* Strömberg et al). 1992;51:527-32

Olson NZ (*see* Sunshine et al). 1992;51:740-6
O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. 1992;51:656-67
—— (*see* Heimark et al). 1992;51:398-407

P

Page RL, Wharton JM, Wilkinson WE, Friedman IM, Claypool WD, Karim A, Kowalski KG, McDonald SJ, Gardiner P, Pritchett ELC. Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. 1992;51:371-8
Palluk R (*see* Schilling et al). 1992;51:541-8
Palmertz MP (*see* Dahl et al). 1992;51:12-7
Passath A (*see* Stoschitzky et al). 1992;51:445-53
Pearce N (*see* Woodman et al). 1992;51:566-71
Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Viswanathan CT, Weissinger J, Yacobi A. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. 1992;51:465-73 (Conference report)
Pennell AT (*see* Clifton et al). 1992;51:296-301
Pérez-Ortíz B (*see* Lares-Asseff et al). 1992;51:42-50
Peyton AL (*see* Bergstrom et al). 1992;51:239-48
Pietrini U (*see* Fanciullacci et al). 1992;51:302-7
Piraino B (*see* Schmith et al). 1992;51:533-40
Portenoy RK, Thaler HT, Inturrisi CE, Friedlander-Klar H, Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. 1992;51:422-31
Porter J (*see* May et al). 1992;51:689-700
Poulos CX (*see* Naranjo et al). 1992;51:729-39
Powell JR (*see* Pritchard et al). 1992;51:51-5
Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. 1992;51:51-5
Pritchett ELC (*see* Clair et al). 1992;51:562-5
—— (*see* Page et al). 1992;51:371-8
Pujade-Lauraine E (*see* Canal et al). 1992;51:249-59
Pussard E (*see* Bellissant et al). 1992;51:308-19

R

Rainsford KD, James C, Hunt RH, Stetsko PI, Rischke JA, Karim A, Nicholson PA, Smith M, Hantsbarger G. Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers. 1992;51:415-21
Ramon M (*see* Canal et al). 1992;51:249-59
Reich MR (*see* Hawkins and Reich). 1992;51:1-11 (Commentary)
Reid JL (*see* Elliott et al). 1992;51:260-5
Reidenberg J (*see* Reidenberg and Reidenberg). 1992;51:747-8
Reidenberg MM, Reidenberg J. 1991 annual report. 1992;51:747-8
Reviriego J (*see* Bertilsson et al). 1992;51:388-97
Richards WO (*see* May et al). 1992;51:689-700
Rieder MJ (*see* Gupta et al). 1992;51:56-67
Rischke JA (*see* Rainsford et al). 1992;51:415-21
Robert J (*see* Canal et al). 1992;51:249-59
Rodman JH (*see* Madden et al). 1992;51:701-7
—— (*see* Peck et al). 1992;51:465-73 (Conference report)
Russel FGM (*see* van Meyel et al). 1992;51:440-4
Ryder D (*see* May et al). 1992;51:689-700

S

Sádaba B (*see* Azanza et al). 1992;51:572-5
Saenger P (*see* Hunt et al). 1992;51:18-23
Sallustio BC (*see* Somogyi et al). 1992;51:379-87
Sanathanan L (*see* Peck et al). 1992;51:465-73 (Conference report)
Santana VM (*see* Madden et al). 1992;51:701-7
Santiago P (*see* Lares-Asseff et al). 1992;51:42-50
Schentag JJ (*see* Peck et al). 1992;51:465-73 (Conference report)
Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. 1992;51:541-8
Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. II. Pharmacodynamics. 1992;51:533-40
Schuster B (*see* Weintraub et al). 1992;51:586-94
—— (*see* Weintraub et al). 1992;51:595-601
—— (*see* Weintraub et al). 1992;51:602-7
—— (*see* Weintraub et al). 1992;51:608-14
—— (*see* Weintraub et al). 1992;51:615-8
—— (*see* Weintraub et al). 1992;51:634-41
Schwartz MK (*see* Forbes et al). 1992;51:343-52
Seppälä T (*see* Strömberg et al). 1992;51:527-32
Shah VP (*see* Peck et al). 1992;51:465-73 (Conference report)
Shapiro BE (*see* Johnson et al). 1992;51:32-41
Shear NH (*see* Gupta et al). 1992;51:56-67
Sheiner LB (*see* Peck et al). 1992;51:465-73 (Conference report)
—— (*see* Uehlinger et al). 1992;51:76-89
Shum LY (*see* Munafo et al). 1992;51:513-21
Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the. 1992;51:288-95
——, ——, ——, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. 1992;51:278-87
Sjöqvist F (*see* Bertilsson et al). 1992;51:388-97
—— (*see* Dahl et al). 1992;51:12-7
Skelly JP (*see* Peck et al). 1992;51:465-73 (Conference report)
Skjelbo E (*see* Sindrup et al). 1992;51:278-87
Sloan R (*see* Fisher et al). 1992;51:677-88
Smith FG (*see* Forbes et al). 1992;51:343-52
Smith M (*see* Rainsford et al). 1992;51:415-21
Smith RA (*see* Zhang et al). 1992;51:647-55
Smith RB (*see* Schmith et al). 1992;51:533-40
Smith WK (*see* Forbes et al). 1992;51:343-52
Smits P (*see* van Meyel et al). 1992;51:440-4
Sommadossi JP (*see* Stagg et al). 1992;51:668-76
Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. 1992;51:379-87
Spielberg SP (*see* Cribb and Spielberg). 1992;51:522-26
—— (*see* Gupta et al). 1992;51:56-67
Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi JP. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine (AMT). 1992;51:668-76
Stanski DR (*see* Peck et al). 1992;51:465-73 (Conference report)
Stave GM (*see* Hunt et al). 1992;51:18-23
Stein EC (*see* Weintraub et al). 1992;51:595-601
—— (*see* Weintraub et al). 1992;51:602-7
—— (*see* Weintraub et al). 1992;51:608-14
—— (*see* Weintraub et al). 1992;51:615-8
Steinmetz JE (*see* Colangelo et al). 1992;51:489-94
—— (*see* Colangelo et al). 1992;51:549-54
Stetsko PI (*see* Rainsford et al). 1992;51:415-21
Stoschitzky K, Lindner W, Egginger G, Brunner F, Obermayer-Pietsch B, Passath A, Klein W. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady rate: hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels. 1992;51:445-53
Stratton CW (*see* Branch et al). 1992;51:481-8 (Commentary)
Strömberg C, Vanakoski J, Olkkola KT, Lindqvist A, Seppälä T, Laitinen LA. Exercise alters the pharmacokinetics of midazolam. 1992;51:527-32
Sundaresan PR (*see* Weintraub et al). 1992;51:586-94

—— (*see* Weintraub et al). 1992;51:595-601
—— (*see* Weintraub et al). 1992;51:602-7
—— (*see* Weintraub et al). 1992;51:608-14
—— (*see* Weintraub et al). 1992;51:615-8
—— (*see* Weintraub et al). 1992;51:619-33
—— (*see* Weintraub et al). 1992;51:634-41
Sunderland M (*see* Madden et al). 1992;51:701-7
Sunshine A, Olson NZ, Zighelboim I, DeCastro A, Minn FL. Analgesic oral efficacy of tramadol hydrochloride in postoperative pain. 1992;51:740-6

T

Tan Y (*see* van Meyel et al). 1992;51:440-4
Tanaka T (*see* Ohnishi et al). 1992;51:454-64
Tasker TCG (*see* Sindrup et al). 1992;51:278-87
Temple RJ (*see* Peck et al). 1992;51:465-73 (Conference report)
Tenhunen R (*see* Mustajoki et al). 1992;51:320-4
Thaler HT (*see* Portenoy et al). 1992;51:422-31
Thuillez C (*see* Bellissant et al). 1992;51:308-19
Tokola O (*see* Mustajoki et al). 1992;51:320-4
Tollefsen E (*see* Klemetsdal et al). 1992;51:24-31
Tonelli A (*see* Johnson et al). 1992;51:32-41
Trager WF (*see* Heimark et al). 1992;51:398-407
—— (*see* O'Reilly et al). 1992;51:656-67
Tresca P (*see* Canal et al). 1992;51:249-59
Troy SM, Hicks DR, Kraml M, Conrad K, Chiang ST. The effect of renal disease on tolrestat pharmacokinetics. 1992;51:271-7
Tuk B (*see* Mandema et al). 1992;51:715-28
Turgeon K (*see* Lown et al). 1992;51:229-38

U

Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. 1992;51:76-89
Uetrecht JP (*see* Gupta et al). 1992;51:56-67
Utsi E (*see* Klemetsdal et al). 1992;51:24-31

V

Valderhaug KL (*see* Zhang et al). 1992;51:647-55
Vanakoski J (*see* Strömberg et al). 1992;51:527-32
van Meyel JJM, Smits P, Russel FGM, Gerlag PGG, Tan Y, Gribnau FWJ. Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. 1992;51:440-4
van Steveninck AL (*see* Mandema et al). 1992;51:715-28
Vincent J, Blaschke TF, Hoffman BB. Vascular reactivity to phenylephrine and angiotensin II: comparison of direct venous and systemic vascular responses. 1992;51:68-75
Viswanathan CT (*see* Peck et al). 1992;51:465-73 (Conference report)

W

Waeber B (*see* Munafo et al). 1992;51:513-21
Wald JA (*see* Fisher et al). 1992;51:677-88
Walker JS (*see* Chay et al). 1992;51:334-42
Wang KY (*see* Bertilsson et al). 1992;51:388-97
Watkins PB (*see* Hunt et al). 1992;51:18-23
—— (*see* Lown et al). 1992;51:229-38
Watlington CO (*see* Hunt et al). 1992;51:18-23
Wedlund PJ (*see* Colangelo et al). 1992;51:489-94
—— (*see* Colangelo et al). 1992;51:549-54
—— (*see* Zhang et al). 1992;51:647-55
Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study—introduction. 1992;51:581-5
——. Long-term weight control study: conclusions. 1992;51:642-6
——, Sundaresan PR, Cox C. Long-term weight control study VI: individual participant response patterns. 1992;51:619-33
——, ——, Madan M, Schuster B, Balder A, Lasagna L, Cox C. Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. 1992;51:586-94
——, ——, Schuster B. Long-term weight control study VII (weeks 0 to 210): serum lipid changes. 1992;51:634-41
——, ——, ——, Averbuch M, Stein EC, Byrne L. Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication. 1992;51:615-8
——, ——, ——, ——, ——, Cox C, Byrne L. Long-term weight control study IV (weeks 156 to 190): the second double-blind phase. 1992;51:608-14
——, ——, ——, Ginsberg G, Madan M, Balder A, Stein EC, Byrne L. Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. 1992;51:595-601
——, ——, ——, Moscucci M, Stein EC. Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine. 1992;51:602-7
Weissinger J (*see* Peck et al). 1992;51:465-73 (Conference report)
Wharton JM (*see* Page et al). 1992;51:371-8
Wienkers L (*see* Heimark et al). 1992;51:398-407
Wilkinson GR (*see* May et al). 1992;51:689-700
Wilkinson WE (*see* Clair et al). 1992;51:562-5
—— (*see* Page et al). 1992;51:371-8
Wiser A (*see* Zahniser et al). 1992;51:432-9
Wist E (*see* Klemetsdal et al). 1992;51:24-31
Woodman K, Pearce N, Beasley R, Burgess C, Crane J. Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study. 1992;51:566-71
Wright JT Jr (*see* Hunt et al). 1992;51:18-23
Wrighton SA (*see* Lown et al). 1992;51:229-38

Y

Yacobi A (*see* Peck et al). 1992;51:465-73 (Conference report)
Yasuda K (*see* Ohnishi et al). 1992;51:454-64

Z

Zahniser NR, Wiser A, Cass WA, Curella P, Gerber JG, Nies AS. Terbutaline-induced desensitization of polymorphonuclear leukocyte β_2-adrenergic receptors in young and elderly subjects. 1992;51:432-9
Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. 1992;51:647-55
Zighelboim I (*see* Sunshine et al). 1992;51:740-6
Zimmerman SW (*see* Johnson et al). 1992;51:32-41
Zussman BD (*see* Sindrup et al). 1992;51:278-87
Zylber-Katz E (*see* Caraco et al). 1992;51:501-6

Subject index

A

Abstracts
Abstracts. 1992;51:121-228

Acadesine
Acadesine (USAN List No. 337). 1992;51:479

Acetylation
The disposition of dapsone in cirrhosis (May et al). 1992;51:689-700

Administration, oral
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (Munafo et al). 1992;51:513-21
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem (Clair et al). 1992;51:562-5

Administration and dosage
Influence of time of administration on verapamil pharmacokinetics (Hla et al). 1992;51:366-70

Age factors
Age and β-adrenergic receptor sensitivity to S(−)- and R,S(±)-propranolol in humans (Colangelo et al). 1992;51:549-54
Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers (Pritchard et al). 1992;51:51-5
Age and propranolol stereoselective disposition in humans (Colangelo et al). 1992;51:489-94

Aged
Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers (Pritchard et al). 1992;51:51-5
Terbutaline-induced desensitization of polymorphonuclear leukocyte β_2-adrenergic receptors in young and elderly subjects (Zahniser et al). 1992;51:432-9

Albuterol
Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study (Woodman et al). 1992;51:566-71

Alcoholism
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers (Naranjo et al). 1992;51:729-39

Aldose reductase
The effect of renal disease on tolrestat pharmacokinetics (Troy et al). 1992;51:271-7

Alprazolam
Alprazolam in end-stage renal disease. II. Pharmacodynamics (Schmith et al). 1992;51:533-40

American Society for Clinical Pharmacology and Therapeutics
A note from the scientific program committee chairperson: submission of abstracts for the 1993 annual meeting. 1992;51:750
Election of officers and committee chairpersons for 1992-1993. 1992;51:749
Future meeting dates and sites of the ASCPT. 1992;51:750
New members of the Society. 1992;51:576-8
Notes of the American Society for Clinical Pharmacology and Therapeutics: a message from the president—come to Orlando, March 18-20, 1992 (Abernethy). 1992;51:93
Presidential address: Orlando, Florida, March 18, 1992 (Abernethy). 1992;51:475-7
Program of the Ninety-third Annual Meeting, March 18-20, 1992, The Peabody Hotel, Orlando, Florida. 1992;51:94-120

Amesergide
Amesergide (USAN List No. 337). 1992;51:480

Amiodarone
The mechanism of the interaction between amiodarone and warfarin in humans (Heimark et al). 1992;51:398-407

Analgesia
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain (Forbes et al). 1992;51:343-52
Analgesic oral efficacy of tramadol hydrochloride in postoperative pain (Sunshine et al). 1992;51:740-6
The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function (Portenoy et al). 1992;51:422-31
Pharmacokinetic-pharmacodynamic relationships of morphine in neonates (Chay et al). 1992;51:334-42

Anemia
A pharmacodynamic model of erythropoietin therapy for uremic anemia (Uehlinger et al). 1992;51:76-89

Angiotensin-converting enzyme inhibitors
Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril (Elliott et al). 1992;51:260-5
Systemic and regional hemodynamic effects of zabicipril in healthy volunteers (Bellissant et al). 1992;51:308-19

Angiotensin II
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (Munafo et al). 1992;51:513-21
Vascular reactivity to phenylephrine and angiotensin II: comparison of direct venous and systemic vascular responses (Vincent et al). 1992;51:68-75

Annual report
1991 annual report (Reidenberg and Reidenberg). 1992;51:747-8

Anorexiants
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study—introduction (Weintraub). 1992;51:581-5
Long-term weight control study: conclusions (Weintraub). 1992;51:642-6
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine (Weintraub et al). 1992;51:602-7
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8
Long-term weight control study VI: individual participant response patterns (Weintraub et al). 1992;51:619-33
Long-term weight control study VII (weeks 0 to 210): serum lipid changes (Weintraub et al). 1992;51:634-41

January, pp. 1-120; February, pp. 121-228; March, pp. 229-358; April, pp. 359-480; May, pp. 481-646; June, pp. 647-768.

Anti-arrhythmia agents
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics (Page et al). 1992;51:371-8
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem (Clair et al). 1992;51:562-5
Antibiotics, anthracycline
Human pharmacokinetics of *N*-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities (Canal et al). 1992;51:249-59
Anticonvulsants
Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides (Gupta et al). 1992;51:56-67
Antidepressive agents, tricyclic
Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction (Bergstrom et al). 1992;51:239-48
Antineoplastic agents
Human pharmacokinetics of *N*-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities (Canal et al). 1992;51:249-59
Antipyrine
Rapid normalization of antipyrine oxidation by heme in variegate porphyria (Mustajoki et al). 1992;51:320-4
Aorta
Differential response of β-adrenergic receptor–mediated heart rate and aortic blood flow acceleration to timolol (Clifton et al). 1992;51:296-301
Arbutamine hydrochloride
Arbutamine hydrochloride (USAN List No. 337). 1992;51:479
Aspirin
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain (Forbes et al). 1992;51:343-52
Asthma
Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study (Woodman et al). 1992;51:566-71
3′-Azido-3′-deoxythymidine; *see* **Zidovudine**

B

Behavior therapy
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8
Beta adrenergic receptors; *see* **Receptors, adrenergic, beta**
Bidisomide
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics (Page et al). 1992;51:371-8
Biotechnology
Biotechnology and therapeutics: expensive treatments and limited resources. A view from the hospital (Meyer). 1992;51:359-65 (Commentary)
Blood flow velocity
Differential response of β-adrenergic receptor–mediated heart rate and aortic blood flow acceleration to timolol (Clifton et al). 1992;51:296-301
Blood vessels
Vascular reactivity to phenylephrine and angiotensin II: comparison of direct venous and systemic vascular responses (Vincent et al). 1992;51:68-75
Bolus injection; *see* **Injections, intravenous**
Breath tests
The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease (Lown et al). 1992;51:229-38
Bromfenac
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain (Forbes et al). 1992;51:343-52
Burns
Pharmacokinetics and pharmacodynamics of ranitidine after burn injury (Martyn et al). 1992;51:408-14

C

Calcipotriene
Calcipotriene (USAN List No. 337). 1992;51:479
Caloric intake
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8
Camiglibose
Camiglibose (USAN List No. 337). 1992;51:478
Cancer; *see* **Neoplasms**
Carbamazepine
Significant weight reduction in obese subjects enhances carbamazepine elimination (Caraco et al). 1992;51:501-6
Carboplatin
The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer (Madden et al). 1992;51:701-7
Cardiovascular system
Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension (Cardillo et al). 1992;51:555-61
Carzelesin
Carzelesin (USAN List No. 337). 1992;51:480
Catecholamines
Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans (Ohnishi et al). 1992;51:454-64
Celiprolol
Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension (Cardillo et al). 1992;51:555-61
Central nervous system
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers (Mandema et al). 1992;51:715-28
Child
The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer (Madden et al). 1992;51:701-7
Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children (Lares-Asseff et al). 1992;51:42-50

China
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin (Bertilsson et al). 1992;51:388-97
Chloroguanide
Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans (Funck-Brentano et al). 1992;51:507-12
Cimetidine
Stereoselective inhibition of pindolol renal clearance by cimetidine in humans (Somogyi et al). 1992;51:379-87
Cioteronel
Cioteronel (USAN List No. 337). 1992;51:480
Circadian rhythm
Influence of time of administration on verapamil pharmacokinetics (Hla et al). 1992;51:366-70
Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 AM versus 4 PM (Fisher et al). 1992;51:677-88
Cirrhosis; *see* Liver cirrhosis
Citalopram
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers (Naranjo et al). 1992;51:729-39
Clinical Pharmacology & Therapeutics
1991 annual report (Reidenberg and Reidenberg). 1992;51:747-8
Commentaries
Commentaries. 1992;51:1-11, 359-65, 481-8
Continuous administration; *see* Infusions, intravenous
Cortisol; *see* Hydrocortisone
Crilvastatin
Crilvastatin (USAN List No. 337). 1992;51:478
Cycloguanil
Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans (Funck-Brentano et al). 1992;51:507-12
Cyclosporins
Possible interaction between cyclosporine and josamycin: a description of three cases (Azanza et al). 1992;51:572-5
CYP3A gene
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol (Hunt et al). 1992;51:18-23
***CYP2D6* gene**
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
Cytochrome P450
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6 (Zhang et al). 1992;51:647-55
The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease (Lown et al). 1992;51:229-38
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol (Hunt et al). 1992;51:18-23
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the (Sindrup et al). 1992;51:288-95
Rapid normalization of antipyrine oxidation by heme in variegate porphyria (Mustajoki et al). 1992;51:320-4
The relationship between paroxetine and the sparteine oxidation polymorphism (Sindrup et al). 1992;51:278-87

D

Dalvastatin
Dalvastatin (USAN List No. 336). 1992;51:356
Dapoxetine hydrochloride
Dapoxetine hydrochloride (USAN List No. 335). 1992;51:92
Dapsone
The disposition of dapsone in cirrhosis (May et al). 1992;51:689-700
Death
Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study (Woodman et al). 1992;51:566-71
Debrisoquin
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin (Bertilsson et al). 1992;51:388-97
Desensitization, immunologic
Terbutaline-induced desensitization of polymorphonuclear leukocyte β_2-adrenergic receptors in young and elderly subjects (Zahniser et al). 1992;51:432-9
Desipramine
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction (Bergstrom et al). 1992;51:239-48
Dextromethorphan
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6 (Zhang et al). 1992;51:647-55
Diabetes mellitus
The effect of renal disease on tolrestat pharmacokinetics (Troy et al). 1992;51:271-7
Diltiazem
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem (Clair et al). 1992;51:562-5
Diuretics
Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers (van Meyel et al). 1992;51:440-4
Dopaminergic agents
Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans (Schilling et al). 1992;51:541-8
Dorzolamide hydrochloride
Dorzolamide hydrochloride (USAN List No. 339). 1992;51:751
Dose-response relationship, drug
An additive or synergistic drug interaction: application of concentration-effect modeling (Meredith and Elliott). 1992;51:708-14
Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril (Elliott et al). 1992;51:260-5
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (Munafo et al). 1992;51:513-21
Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine (Weintraub et al). 1992;51:602-7
The method of relative drug accumulation: a simple method for illustrating the effects of different drug dosing regimens and variability in drug elimination on time courses of drug concentrations (Bjornsson). 1992;51:266-70
Doxorubicin
Human pharmacokinetics of *N*-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities (Canal et al). 1992;51:249-59
Drug concentration
The method of relative drug accumulation: a simple method for illustrating the effects of different drug dosing regimens and variability in drug elimination on time courses of drug concentrations (Bjornsson). 1992;51:266-70

Drug design
An additive or synergistic drug interaction: application of concentration-effect modeling (Meredith and Elliott). 1992;51:708-14
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development (Peck et al). 1992;51:465-73 (Conference report)
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers (Mandema et al). 1992;51:715-28
Drug development; *see* **Drug design**
Drug hypersensitivity
Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides (Gupta et al). 1992;51:56-67
Sulfamethoxazole is metabolized to the hydroxylamine in humans (Cribb and Spielberg). 1992;51:522-26
Drug industry
Japanese-originated pharmaceutical products in the United States from 1960 to 1989: an assessment of innovation (Hawkins and Reich). 1992;51:1-11 (Commentary)
Drug interactions
An additive or synergistic drug interaction: application of concentration-effect modeling (Meredith and Elliott). 1992;51:708-14
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6 (Zhang et al). 1992;51:647-55
Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers (Rainsford et al). 1992;51:415-21
The mechanism of the interaction between amiodarone and warfarin in humans (Heimark et al). 1992;51:398-407
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects (O'Reilly et al). 1992;51:656-67
Possible interaction between cyclosporine and josamycin: a description of three cases (Azanza et al). 1992;51:572-5
Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction (Bergstrom et al). 1992;51:239-48
Stereoselective inhibition of pindolol renal clearance by cimetidine in humans (Somogyi et al). 1992;51:379-87
Theophylline toxicity after propafenone treatment: evidence for drug interaction (Lee and Dohrmann). 1992;51:353-5
Drug synergism
An additive or synergistic drug interaction: application of concentration-effect modeling (Meredith and Elliott). 1992;51:708-14
Drug tolerance
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics (Page et al). 1992;51:371-8

E

Education
The formulary: an educational tool for clinical pharmacology (Branch et al). 1992;51:481-8 (Commentary)
Presidential address: Orlando, Florida, March 18, 1992 (Abernethy). 1992;51:475-77
Eicosanoids
Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans (Ohnishi et al). 1992;51:454-64
Elderly; *see* **Aged**
End-stage renal disease; *see* **Kidney failure, chronic**
Ephedrine
Exercise alters the pharmacokinetics of midazolam (Strömberg et al). 1992;51:527-32
Ergotamine
Long-term ergotamine abuse: effect on adrenergically induced mydriasis (Fanciullacci et al). 1992;51:302-7
Erythromycin
The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease (Lown et al). 1992;51:229-38
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol (Hunt et al). 1992;51:18-23
Erythropoietin
A pharmacodynamic model of erythropoietin therapy for uremic anemia (Uehlinger et al). 1992;51:76-89
Ethnic characteristics
Interethnic difference in thiopurine methyltransferase activity (Klemetsdal et al). 1992;51:24-31
Etoposide phosphate
Etoposide phosphate (USAN List No. 339). 1992;51:752
Exercise
Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans (Ohnishi et al). 1992;51:454-64
Exercise alters the pharmacokinetics of midazolam (Strömberg et al). 1992;51:527-32
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8

F

Famotidine
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure (Kirch et al). 1992;51:325-33
Felodipine
Felodipine (USAN List No. 338). 1992;51:579
Fenfluramine
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study—introduction (Weintraub). 1992;51:581-5
Long-term weight control study: conclusions (Weintraub). 1992;51:642-6
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine (Weintraub et al). 1992;51:602-7
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14

Fenfluramine—cont'd
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8
Long-term weight control study VI: individual participant response patterns (Weintraub et al). 1992;51:619-33
Long-term weight control study VII (weeks 0 to 210): serum lipid changes (Weintraub et al). 1992;51:634-41
Ferumoxides
Ferumoxides (USAN List No. 339). 1992;51:752
Ferumoxsil
Ferumoxsil (USAN List No. 339). 1992;51:752
Fluoxetine
Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction (Bergstrom et al). 1992;51:239-48
Formularies, hospital
The formulary: an educational tool for clinical pharmacology (Branch et al). 1992;51:481-8 (Commentary)
Furosemide
Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers (van Meyel et al). 1992;51:440-4

G

Gallium nitrate
Gallium nitrate (USAN List No. 338). 1992;51:579
Gender; *see* Sex
Genetics
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol (Hunt et al). 1992;51:18-23
Interethnic difference in thiopurine methyltransferase activity (Klemetsdal et al). 1992;51:24-31
Glucuronates
The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function (Portenoy et al). 1992;51:422-31
Glucuronides; *see* Glucuronates
Granisetron
Granisetron (USAN List No. 335). 1992;51:91
Granisetron hydrochloride
Granisetron hydrochloride (USAN List No. 338). 1992;51:579
Guest reviewers
Guest reviewers. 1992;51:474

H

Health resources
Biotechnology and therapeutics: expensive treatments and limited resources. A view from the hospital (Meyer). 1992;51:359-65 (Commentary)
Heart failure, congestive
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure (Kirch et al). 1992;51:325-33
Heart rate
Differential response of β-adrenergic receptor–mediated heart rate and aortic blood flow acceleration to timolol (Clifton et al). 1992;51:296-301
Heme
Rapid normalization of antipyrine oxidation by heme in variegate porphyria (Mustajoki et al). 1992;51:320-4
Hemodynamics
Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension (Cardillo et al). 1992;51:555-61
Exercise alters the pharmacokinetics of midazolam (Strömberg et al). 1992;51:527-32
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure (Kirch et al). 1992;51:325-33
Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels (Stoschitzky et al). 1992;51:445-53
Systemic and regional hemodynamic effects of zabicipril in healthy volunteers (Bellissant et al). 1992;51:308-19
HIV
Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine (AMT) (Stagg et al). 1992;51:668-76
Hydrocortisone
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol (Hunt et al). 1992;51:18-23
Hydrogen-ion concentration
Pharmacokinetics and pharmacodynamics of ranitidine after burn injury (Martyn et al). 1992;51:408-14
Hydroxylamines
Sulfamethoxazole is metabolized to the hydroxylamine in humans (Cribb and Spielberg). 1992;51:522-26
Hydroxylation
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
The disposition of dapsone in cirrhosis (May et al). 1992;51:689-700
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin (Bertilsson et al). 1992;51:388-97
Hydroxymidazolam
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers (Mandema et al). 1992;51:715-28
Hypersensitivity reactions; *see* Drug hypersensitivity
Hypertension
Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension (Cardillo et al). 1992;51:555-61
Hypothyroidism
Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides (Gupta et al). 1992;51:56-67

I

Ibuprofen
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain (Forbes et al). 1992;51:343-52
Imipramine
Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction (Bergstrom et al). 1992;51:239-48
Imiquimod
Imiquimod (USAN List No. 335). 1992;51:91
Indomethacin
Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers (Rainsford et al). 1992;51:415-21
Infant, newborn
Pharmacokinetic-pharmacodynamic relationships of morphine in neonates (Chay et al). 1992;51:334-42
Infusions, intravenous
Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers (van Meyel et al). 1992;51:440-4

Injections, intravenous
Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers (van Meyel et al). 1992;51:440-4
Interactions; *see* **Drug interactions**
Interethnic differences; *see* **Ethnic characteristics**

J

Japan
Japanese-originated pharmaceutical products in the United States from 1960 to 1989: an assessment of innovation (Hawkins and Reich). 1992;51:1-11 (Commentary)
Josamycin
Possible interaction between cyclosporine and josamycin: a description of three cases (Azanza et al). 1992;51:572-5

K

Kidney
The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function (Portenoy et al). 1992;51:422-31
Stereoselective inhibition of pindolol renal clearance by cimetidine in humans (Somogyi et al). 1992;51:379-87
Kidney diseases
The effect of renal disease on tolrestat pharmacokinetics (Troy et al). 1992;51:271-7
Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease (Johnson et al). 1992;51:32-41
Kidney failure, chronic
Alprazolam in end-stage renal disease. II. Pharmacodynamics (Schmith et al). 1992;51:533-40

L

Lipids
Long-term weight control study VII (weeks 0 to 210): serum lipid changes (Weintraub et al). 1992;51:634-41
Liver cirrhosis
The disposition of dapsone in cirrhosis (May et al). 1992;51:689-700
Liver diseases
The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease (Lown et al). 1992;51:229-38
Liver microsomes; *see* **Microsomes, liver**
Losartan
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (Munafo et al). 1992;51:513-21
Losartan potassium
Losartan potassium (USAN List No. 339). 1992;51:752

M

Malnutrition; *see* **Nutrition disorders**
Mephenytoin
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin (Bertilsson et al). 1992;51:388-97
Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans (Funck-Brentano et al). 1992;51:507-12
Methylprednisolone
Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 AM versus 4 PM (Fisher et al). 1992;51:677-88
Metronidazole
Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children (Lares-Asseff et al). 1992;51:42-50
Miconazole
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects (O'Reilly et al). 1992;51:656-67
Microsomes, liver
Sulfamethoxazole is metabolized to the hydroxylamine in humans (Cribb and Spielberg). 1992;51:522-26
Midazolam
Exercise alters the pharmacokinetics of midazolam (Strömberg et al). 1992;51:527-32
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers (Mandema et al). 1992;51:715-28
Misoprostol
Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers (Rainsford et al). 1992;51:415-21
Modeling; *see* **Drug design**
Monoctanoin
Monoctanoin (USAN List No. 338). 1992;51:580
Morphine
The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function (Portenoy et al). 1992;51:422-31
Pharmacokinetic-pharmacodynamic relationships of morphine in neonates (Chay et al). 1992;51:334-42
Mydriasis
Long-term ergotamine abuse: effect on adrenergically induced mydriasis (Fanciullacci et al). 1992;51:302-7

N

Neoplasms
Human pharmacokinetics of *N*-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities (Canal et al). 1992;51:249-59
The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer (Madden et al). 1992;51:701-7
Neuroendocrine system; *see* **Neurosecretory systems**
Neurosecretory systems
Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans (Schilling et al). 1992;51:541-8
Neutrophils
Terbutaline-induced desensitization of polymorphonuclear leukocyte β_2-adrenergic receptors in young and elderly subjects (Zahniser et al). 1992;51:432-9
Nevirapine
Nevirapine (USAN List No. 335). 1992;51:91
New Zealand
Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study (Woodman et al). 1992;51:566-71
Nutrition disorders
Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children (Lares-Asseff et al). 1992;51:42-50

O

Obesity
Significant weight reduction in obese subjects enhances carbamazepine elimination (Caraco et al). 1992;51:501-6
Olanzapine
Olanzapine (USAN List No. 339). 1992;51:751

Ondansetron
Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers (Pritchard et al). 1992;51:51-5
Oral administration; *see* **Administration, oral**
Orlistat
Orlistat (USAN List No. 335). 1992;51:90

P

Pain
The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function (Portenoy et al). 1992;51:422-31
Pain, postoperative
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain (Forbes et al). 1992;51:343-52
Analgesic oral efficacy of tramadol hydrochloride in postoperative pain (Sunshine et al). 1992;51:740-6
Pharmacokinetic-pharmacodynamic relationships of morphine in neonates (Chay et al). 1992;51:334-42
Paroxetine
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the (Sindrup et al). 1992;51:288-95
The relationship between paroxetine and the sparteine oxidation polymorphism (Sindrup et al). 1992;51:278-87
Paroxysmal supraventricular tachycardia; *see* **Tachycardia, paroxysmal**
Pediatrics; *see* **Child**
Perflubron
Perflubron (USAN List No. 335). 1992;51:92
Perfosfamide
Perfosfamide (USAN List No. 335). 1992;51:92
pH; *see* **Hydrogen-ion concentration**
Pharmaceutical industry; *see* **Drug industry**
Pharmacodynamics
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development (Peck et al). 1992;51:465-73 (Conference report)
Pharmacokinetics
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development (Peck et al). 1992;51:465-73 (Conference report)
Phentermine
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study—introduction (Weintraub). 1992;51:581-5
Long-term weight control study: conclusions (Weintraub). 1992;51:642-6
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine (Weintraub et al). 1992;51:602-7
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8
Long-term weight control study VI: individual participant response patterns (Weintraub et al). 1992;51:619-33
Long-term weight control study VII (weeks 0 to 210): serum lipid changes (Weintraub et al). 1992;51:634-41
Phenylephrine
Long-term ergotamine abuse: effect on adrenergically induced mydriasis (Fanciullacci et al). 1992;51:302-7
Vascular reactivity to phenylephrine and angiotensin II: comparison of direct venous and systemic vascular responses (Vincent et al). 1992;51:68-75
Pindolol
Stereoselective inhibition of pindolol renal clearance by cimetidine in humans (Somogyi et al). 1992;51:379-87
Piperacillin
Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease (Johnson et al). 1992;51:32-41
Placebos
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Plasma
Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady rate: hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels (Stoschitzky et al). 1992;51:445-53
Platelet aggregation
Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans (Ohnishi et al). 1992;51:454-64
Polymorphic hydroxylation; *see* **Hydroxylation**
Polymorphism
Interethnic difference in thiopurine methyltransferase activity (Klemetsdal et al). 1992;51:24-31
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the (Sindrup et al). 1992;51:288-95
The relationship between paroxetine and the sparteine oxidation polymorphism (Sindrup et al). 1992;51:278-87
Polymorphonuclear leukocytes; *see* **Neutrophils**
Porphyria
Rapid normalization of antipyrine oxidation by heme in variegate porphyria (Mustajoki et al). 1992;51:320-4
Postoperative pain; *see* **Pain, postoperative**
Pramipexole
Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans (Schilling et al). 1992;51:541-8
Prazosin
An additive or synergistic drug interaction: application of concentration-effect modeling (Meredith and Elliott). 1992;51:708-14
Presidential address
Presidential address: Orlando, Florida, March 18, 1992 (Abernethy). 1992;51:475-77
Propafenone
Theophylline toxicity after propafenone treatment: evidence for drug interaction (Lee and Dohrmann). 1992;51:353-5
Propranolol
Age and β-adrenergic receptor sensitivity to S(−)- and R,S(±)-propranolol in humans (Colangelo et al). 1992;51:549-54
Age and propranolol stereoselective disposition in humans (Colangelo et al). 1992;51:489-94
Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady rate: hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels (Stoschitzky et al). 1992;51:445-53
Racial differences in propranolol pharmacokinetics (Johnson and Burlew). 1992;51:495-500

Protein binding
Age and propranolol stereoselective disposition in humans (Colangelo et al). 1992;51:489-94
Racial differences in propranolol pharmacokinetics (Johnson and Burlew). 1992;51:495-500

Q

Quinapril
Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril (Elliott et al). 1992;51:260-5
Quinidine
Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6 (Zhang et al). 1992;51:647-55
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure (Kirch et al). 1992;51:325-33

R

Racemic propranolol; *see* **Propranolol**
Racemic warfarin; *see* **Warfarin**
Racial factors
Racial differences in propranolol pharmacokinetics (Johnson and Burlew). 1992;51:495-500
Ralitoline
Ralitoline (USAN List No. 335). 1992;51:92
Ranitidine
Pharmacokinetics and pharmacodynamics of ranitidine after burn injury (Martyn et al). 1992;51:408-14
Receptors, adrenergic, beta
Age and β-adrenergic receptor sensitivity to S(−)- and R,S(±)-propranolol in humans (Colangelo et al). 1992;51:549-54
Differential response of β-adrenergic receptor–mediated heart rate and aortic blood flow acceleration to timolol (Clifton et al). 1992;51:296-301
Terbutaline-induced desensitization of polymorphonuclear leukocyte β_2-adrenergic receptors in young and elderly subjects (Zahniser et al). 1992;51:432-9
Receptors, angiotensin
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist (Munafo et al). 1992;51:513-21
Receptors, dopamine
Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans (Schilling et al). 1992;51:541-8
Relative drug accumulation
The method of relative drug accumulation: a simple method for illustrating the effects of different drug dosing regimens and variability in drug elimination on time courses of drug concentrations (Bjornsson). 1992;51:266-70
Renal diseases; *see* **Kidney diseases**
Renal function; *see* **Kidney**
Report
1991 annual report (Reidenberg and Reidenberg). 1992;51:747-8
Research
Presidential address: Orlando, Florida, March 18, 1992 (Abernethy). 1992;51:475-77
Resources; *see* **Health resources**
Reviewers
Guest reviewers. 1992;51:474
R,S-propranolol; *see* **Propranolol**

S

S-mephenytoin; *see* **Mephenytoin**
S-propranolol; *see* **Propranolol**
Serotonin
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the (Sindrup et al). 1992;51:288-95
The relationship between paroxetine and the sparteine oxidation polymorphism (Sindrup et al). 1992;51:278-87
Serotonin antagonists
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers (Naranjo et al). 1992;51:729-39
Sex
Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers (Pritchard et al). 1992;51:51-5
Somfasepor
Somfasepor (USAN List No. 336). 1992;51:356
Sparfloxacin
Sparfloxacin (USAN List No. 337). 1992;51:478
Sparteine
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the (Sindrup et al). 1992;51:288-95
The relationship between paroxetine and the sparteine oxidation polymorphism (Sindrup et al). 1992;51:278-87
Stress
Effects of celiprolol on cardiovascular reactivity to laboratory stressors in patients with hypertension (Cardillo et al). 1992;51:555-61
Substance abuse
Long-term ergotamine abuse: effect on adrenergically induced mydriasis (Fanciullacci et al). 1992;51:302-7
Sulfamethoxazole
Sulfamethoxazole is metabolized to the hydroxylamine in humans (Cribb and Spielberg). 1992;51:522-26
Sulfonamides
Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides (Gupta et al). 1992;51:56-67
Surgery, oral
Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain (Forbes et al). 1992;51:343-52
Sweden
Analysis of the *CYP2D6* gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population (Dahl et al). 1992;51:12-7
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin (Bertilsson et al). 1992;51:388-97
Synergism; *see* **Drug synergism**

T

Tachycardia, paroxysmal
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem (Clair et al). 1992;51:562-5
Tazobactam
Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease (Johnson et al). 1992;51:32-41
Terbutaline
Terbutaline-induced desensitization of polymorphonuclear leukocyte β_2-adrenergic receptors in young and elderly subjects (Zahniser et al). 1992;51:432-9
Terlakiren
Terlakiren (USAN List No. 335). 1992;51:90
Theophylline
Theophylline toxicity after propafenone treatment: evidence for drug interaction (Lee and Dohrmann). 1992;51:353-5

Therapeutics
Biotechnology and therapeutics: expensive treatments and limited resources. A view from the hospital (Meyer). 1992;51:359-65 (Commentary)
Thiopurine methyltransferase
Interethnic difference in thiopurine methyltransferase activity (Klemetsdal et al). 1992;51:24-31
Thromboxane synthetase
Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans (Ohnishi et al). 1992;51:454-64
Thyroid gland
Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides (Gupta et al). 1992;51:56-67
Thyroid hormones
Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady rate: hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels (Stoschitzky et al). 1992;51:445-53
Timolol
Differential response of β-adrenergic receptor–mediated heart rate and aortic blood flow acceleration to timolol (Clifton et al). 1992;51:296-301
Tolerability; *see* **Drug tolerance**
Tolrestat
The effect of renal disease on tolrestat pharmacokinetics (Troy et al). 1992;51:271-7
Toxicity
Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine (AMT) (Stagg et al). 1992;51:668-76
Human pharmacokinetics of *N*-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities (Canal et al). 1992;51:249-59
Theophylline toxicity after propafenone treatment: evidence for drug interaction (Lee and Dohrmann). 1992;51:353-5
Toxicokinetics
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development (Peck et al). 1992;51:465-73 (Conference report)
Tramadol
Analgesic oral efficacy of tramadol hydrochloride in postoperative pain (Sunshine et al). 1992;51:740-6
Tyramine
Long-term ergotamine abuse: effect on adrenergically induced mydriasis (Fanciullacci et al). 1992;51:302-7

U

United States Adopted Names Council
USAN Council. 1992;51:90-2, 356-8, 479-80, 579-80, 751-2
Uremia
A pharmacodynamic model of erythropoietin therapy for uremic anemia (Uehlinger et al). 1992;51:76-89

V

Vascular response; *see* **Blood vessels**
Venous response; *see* **Blood vessels**
Verapamil
An additive or synergistic drug interaction: application of concentration-effect modeling (Meredith and Elliott). 1992;51:708-14
Influence of time of administration on verapamil pharmacokinetics (Hla et al). 1992;51:366-70

W

Warfarin
The mechanism of the interaction between amiodarone and warfarin in humans (Heimark et al). 1992;51:398-407
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects (O'Reilly et al). 1992;51:656-67
Weight control
Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study—introduction (Weintraub). 1992;51:581-5
Long-term weight control study: conclusions (Weintraub). 1992;51:642-6
Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo (Weintraub et al). 1992;51:586-94
Long-term weight control study II (weeks 34 to 104): an open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise (Weintraub et al). 1992;51:595-601
Long-term weight control study III (weeks 104 to 156): an open-label study of dose adjustment of fenfluramine and phentermine (Weintraub et al). 1992;51:602-7
Long-term weight control study IV (weeks 156 to 190): the second double-blind phase (Weintraub et al). 1992;51:608-14
Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication (Weintraub et al). 1992;51:615-8
Long-term weight control study VI: individual participant response patterns (Weintraub et al). 1992;51:619-33
Long-term weight control study VII (weeks 0 to 210): serum lipid changes (Weintraub et al). 1992;51:634-41
Significant weight reduction in obese subjects enhances carbamazepine elimination (Caraco et al). 1992;51:501-6

X

Xenobiotics
Rapid normalization of antipyrine oxidation by heme in variegate porphyria (Mustajoki et al). 1992;51:320-4

Z

Zabicipril
Systemic and regional hemodynamic effects of zabicipril in healthy volunteers (Bellissant et al). 1992;51:308-19
Zalcitabine
Zalcitabine (USAN List No. 335). 1992;51:91
Zanoterone
Zanoterone (USAN List No. 339). 1992;51:751
Zidovudine
Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine (AMT) (Stagg et al). 1992;51:668-76